Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipatasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 known ✓ | Q9Y243 | 20/20 | 0.98 |
| ▸ | AKT1 known ✓ | P31749 | 19/20 | 0.98 |
| ▸ | AKT2 known ✓ | P31751 | 19/20 | 0.98 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.98 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipatasertib SCHEMBL21900357 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL29393010 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL15390324 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191805 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL1740213 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL15390761 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL192342 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL21900358 | 1.00 | AKT3 (0.98) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191491 | 0.99 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL17424852 | 0.99 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118812510-A | SOS1 protein degradation agent and application thereof | 上海科技大学 | 2024-10-22 | — | — | CN | claimed |
| EP-4667499-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4232463-B1 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250195855-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2025-06-19 | — | — | US | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| EP-4512394-A2 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2025-02-26 | — | — | EP | disclosed |
| EP-4493258-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-20240408023-A1 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4171518-B1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4232463-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2023-05-18 | — | — | US | disclosed |
| EP-4171518-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11433022-B2 | Rapidly-orodispersible tablets having an in interior cavity | Aprecia Pharmaceuticals LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220125884-A1 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022087149-A2 | INTERLEUKIN-2-FC FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3981392-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2022-04-13 | — | — | EP | disclosed |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | Triastek, Inc. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20220054409-A1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | MUC1, SLC10A2, FABP2 | AKT3 4724/4885AKT1 4856/4885AKT2 4270/4885 |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | AKT3 2240/4885AKT1 2347/4885AKT2 2161/4885 |
| US-11278499-B2 | Oral drug dosage form comprising various release profiles | CYP2D6, CYP3A7, CYP3A5 | AKT3 4119/4885AKT1 4080/4885AKT2 3653/4885 |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | MUC1, SLC10A2, FABP2 | AKT3 4724/4885AKT1 4856/4885AKT2 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.